213 related articles for article (PubMed ID: 37098481)
21. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
Yu Y; Xu X; Du Z; Shi M
Cancer Chemother Pharmacol; 2012 May; 69(5):1265-75. PubMed ID: 22297708
[TBL] [Abstract][Full Text] [Related]
22. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer.
Kobayashi S; Ueno M; Sugimori K; Morizane C; Kojima Y; Irie K; Goda Y; Morimoto M; Ohkawa S
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1189-1196. PubMed ID: 29071413
[TBL] [Abstract][Full Text] [Related]
24. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
[TBL] [Abstract][Full Text] [Related]
25. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A
Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689
[TBL] [Abstract][Full Text] [Related]
26. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
[TBL] [Abstract][Full Text] [Related]
27. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
Luvira V; Satitkarnmanee E; Pugkhem A; Kietpeerakool C; Lumbiganon P; Pattanittum P
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD012814. PubMed ID: 34515993
[TBL] [Abstract][Full Text] [Related]
28. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
[TBL] [Abstract][Full Text] [Related]
29. Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
Chung MJ; Kim YJ; Park JY; Bang S; Song SY; Chung JB; Park SW
Chemotherapy; 2011; 57(3):236-43. PubMed ID: 21597288
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis.
Yang R; Wang B; Chen YJ; Li HB; Hu JB; Zou SQ
Anticancer Drugs; 2013 Sep; 24(8):871-7. PubMed ID: 23799294
[TBL] [Abstract][Full Text] [Related]
31. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Ito Y; Kogure H; Togawa O; Toda N; Yasuda I; Hasebe O; Maetani I; Sasahira N; Hirano K; Tsujino T; Tada M; Omata M
Cancer Chemother Pharmacol; 2010 May; 65(6):1101-7. PubMed ID: 19707761
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).
Yang J; He J; Yu M; Li T; Luo L; Liu P
Medicine (Baltimore); 2016 Dec; 95(50):e5599. PubMed ID: 27977596
[TBL] [Abstract][Full Text] [Related]
33. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Sakai D; Kodama Y; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2012 May; 69(5):1181-8. PubMed ID: 22237958
[TBL] [Abstract][Full Text] [Related]
35. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.
Thongprasert S; Napapan S; Charoentum C; Moonprakan S
Ann Oncol; 2005 Feb; 16(2):279-81. PubMed ID: 15668284
[TBL] [Abstract][Full Text] [Related]
37. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
[TBL] [Abstract][Full Text] [Related]
38. Kanglaite injection plus fluorouracil-based chemotherapy on the reduction of adverse effects and improvement of clinical effectiveness in patients with advanced malignant tumors of the digestive tract: A meta-analysis of 20 RCTs following the PRISMA guidelines.
Song Q; Zhang J; Wu Q; Li G; Leung EL
Medicine (Baltimore); 2020 Apr; 99(17):e19480. PubMed ID: 32332600
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
de Castria TB; da Silva EM; Gois AF; Riera R
Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
